BioTech stock promoted by Jeff BrownIn his research, Jeff learned the U.S. military โ along with Google and Bill Gates โ placed big bets on a tiny biotech company.
It’s no coincidence the FDA recently fast-tracked this company’s new drug.
It’s set to be the biggest medical breakthrough in decades.
A next generation antibiotic โ the first of its kind since the 1980s.
It’s now almost ready to hit the market. The company is just waiting for the final go-ahead from the FDA.
The announcement is due in the third quarter. Possibly as early as this month.
Any idea who he is referring to?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Can someone please comment Iโve been trying to figure this out for a month
This was from an April 2020 article on Gumshoe: Spero Therapeutics (SPRO), a little antibiotic developer with a small pipeline of antibiotics led by Tebipenem HBr, which is currently in Phase 3 trials with the expectation of โtopline dataโ being released in the third quarter (they also have a couple other anti-infectives on Phase 1, but Tebipenem is the big oneโฆ and the relatively safer one, since itโs been approved in Japan since 2009 โ Spero effectively went public on the strength of some venture funding and the US license for this drug,ย which they bought cheap, in late 2017).
Thank you
SPRO is the ticker. Newest antibiotic since the 1980โs.
Thank you!
what’s the latest?
I have not read JB’s report, but I believe the genomic stock he is talking about is one of three gene-editing stocks all of whom share in the ownership of a patent on a process known as CRISPER CAS-9 . They were involved in a court fight some time ago and finally, the courts granted them joint ownership. The process allows them to “edit” a gene the way we might edit a manuscript, lust cutting out a portion and replacing it with a corrected piece. The three companies are CRSP (Crisper), NTLA (Intellia), and EDIT, (Editas). All of them are worth investing in but the winner over the last couple of months is EDIT, as they are expecting an announcement from the FDA that will allow them to start clinical trials on a gene-editing process designed to cure some kinds of blindness. The news has leaked out and the first move has been accomplished but JB’s teaser claims a much larger move will take place. I bought the stock early on before it actually broke out because I became interested in the group due to their patents, so I bought both EDIT and NTLA, and I’ll buy CRSP when it pulls back enough. The woman that developed the process won the Nobel Prize for it.
I bought ยฃ10K Editas in 16th Nov and have this tripled my investment. Thatโs BEFORE final FDA approval of EDIT-101 for LCA10 genetic blindness. So yes, even higher hopes for this stock.
EDIT: Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference. See link below:
https://mail.google.com/mail/u/0/?q=in%3Asent+etcg+fork#inbox/FMfcgxwKkRBXGHlHXfKGKRgkPbrbQnvX
SPRO is another one of Jeff Brown’s recommendations from his Exponential Tech Investor service, but IT IS NOT the stock referred to on his big genomics teaser. That stock is EDIT (EDITAS) see my post from a couple of days ago. I am about to buy SPRO as well as the genomics subgroup of the biotech group is extremely hot and may remain so for months and perhaps years. The top performers in the health Care Sector come from biotech/genomics and it seems to be where the relative strength is for some time to come. the XBI ETF had been dormant for nearly five years prior to its breakout in May 2020, I think this is the opening move in a multi-year trend, IMHO.
My suggestion is to consider Catherine Woodโs ARK Genomic Revolution ETF (ARKG). it will give you exposure to all names mentioned above.
I NEED TEEKI TEWIA PRE-IPO I CANT FIND IT ON HERE AND I NEED ASAP AND PHONE NUMBER,PLEASE HELP I THANK YOU VERY MUCH!!!
I think it is Robot Cache. It is sold out, but you can get on a waiting list for the next round of funding, if it gets approved.